Free tool
FAERS Monitor: Prilosec Otc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021229 or its brand name (Prilosec Otc, Omeprazole Magnesium). Reports on generic versions are filed under their own applications.
Reports
31,002
Serious
23,793
77% of reports
Hospitalization
3,499
Death reported
2,661
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease18,104
- acute kidney injury9,430
- renal failure7,624
- end stage renal disease5,802
- renal injury5,352
- tubulointerstitial nephritis2,343
- hyperchlorhydria2,167
- pain2,132
- rebound effect2,006
- gastrooesophageal reflux disease1,959
- drug ineffective1,699
- drug dependence1,679
- nephrogenic anaemia1,509
- death1,335
- rebound acid hypersecretion1,292
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 55 |
| 2006 | 65 |
| 2007 | 87 |
| 2008 | 229 |
| 2009 | 603 |
| 2010 | 438 |
| 2011 | 691 |
| 2012 | 1,229 |
| 2013 | 623 |
| 2014 | 570 |
| 2015 | 683 |
| 2016 | 634 |
| 2017 | 538 |
| 2018 | 9,084 |
| 2019 | 8,419 |
| 2020 | 2,576 |
| 2021 | 1,906 |
| 2022 | 660 |
| 2023 | 373 |
| 2024 | 390 |
| 2025 | 582 |
| 2026 | 530 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rebound acid hypersecretionSignal | 1,292 | 504.7 | 470.0 | 372,117 |
| hyperchlorhydriaSignal | 2,167 | 394.6 | 374.7 | 537,716 |
| nephrogenic anaemiaSignal | 1,509 | 327.1 | 308.0 | 330,824 |
| end stage renal diseaseSignal | 5,802 | 315.9 | 306.8 | 1,243,317 |
| chronic kidney diseaseSignal | 18,104 | 211.8 | 209.2 | 2,905,026 |
| renal injurySignal | 5,352 | 148.8 | 144.8 | 645,127 |
| rebound effectSignal | 2,006 | 146.2 | 139.5 | 237,949 |
| tubulointerstitial nephritisSignal | 2,343 | 96.8 | 92.8 | 194,435 |
| acute kidney injurySignal | 9,430 | 44.5 | 43.7 | 378,863 |
| renal failureSignal | 7,624 | 41.3 | 40.4 | 284,074 |
| gastrooesophageal reflux diseaseSignal | 1,959 | 16.9 | 16.2 | 28,679 |
| drug dependenceSignal | 1,679 | 7.1 | 6.8 | 8,848 |
| painSignal | 2,132 | 2.4 | 2.3 | 1,713 |
| death | 1,335 | 1.1 | 1.0 | 3 |
| drug ineffective | 1,699 | 0.9 | 0.8 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.